The Weill Cornell Medicine Comprehensive Thalassemia Center staff members are committed to the safety and well-being of our patients. For more information about COVID-19, here are links to other sources: the Weill Cornell COVID-19 patient guide, the Centers for Disease Control (CDC) website, the NYC Department of Health website, and the Cooley's Anemia Foundation website. These sources provide up-to-date information on signs and symptoms, precautions to take, when to quarantine and other important tips. If you have developed a fever, cough, shortness of breath or other respiratory symptoms, please call your provider right away.
New York Comprehensive Thalassemia Center

You are here

Upcoming Clinical Trials

Evaluate the Efficacy and Safety of Red Blood Cells (RBCs) Derived from Mirasol-Treated Whole Blood Compared with Conventional RBCs in Patients Requiring Chronic Transfusion Support (PRAISE Trial)

Primary Investigator: Sujit Sheth
This prospective, multi-center, randomized, crossover trial will evaluate the clinical effectiveness of RBCs derived from Mirasol-treated whole blood versus conventional whole-blood-derived RBCs in transfusion-dependent thalassemia patients. Throughout the clinical study, whole-blood-derived RBC transfusion volume and frequency will be determined by each subject's physician. Eligible subjects who have signed an informed or parental consent form, and assent form where applicable, will be enrolled and randomized 1:1 to a treatment sequence via an electronic system using a permuted-block schedule stratified by investigational site. Subjects will be randomized to receive either RBCs derived from Mirasol-treated whole blood followed by conventional RBCs, or to receive conventional RBCs followed by RBCs derived from Mirasol-treated whole blood.

New York Comprehensive Thalassemia Center of Weill Cornell Medicine 525 E. 68th St.
Payson 695
New York, NY 10065 Phone: (212) 746-3400